Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective conscientiously but unsuccessfully to develop a single therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be used is an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination treatment in the healing of multi-drug-resistant HIV have been closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the past few shares of mine. My 1st CytoDyn article, “CytoDyn: What To Do When It’s Too Good to be able to Be True?”, set away the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly promotional picture in the Uptick Newswire job interview that I came away with an inadequate opinion of the business.

Irony of irony, my poor viewpoint of the business has grown steadily, however, the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger yet still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the therapy as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of this technology and associated intellectual property coming from Progenics to CytoDyn, and approximately twenty five million mg of majority drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 million) plus the very first new drug application approval ($5 million), and also royalty payments of five percent of net sales after commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and many therapies, it has this individual therapies as well as a “broad pipeline of indications” as it puts it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially advantageous therapy in dozens of indications.

Its opening banner on its site (below) shows an energetic business with diverse interests albeit centered on leronlimab, several disease sorts, multiple publications and multiple presentations.

Could all of it be smoke and mirrors? That is a question I have been asking myself through the very start of my interest in this particular organization. Judging by way of the multiples of thousands of various comments on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am much from alone in this question.

CytoDyn is a traditional battleground, or maybe some may say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *